Successful Treatment of a Patient With Chronic Bronchiectasis Using an Induced Native Phage Cocktail: A Case Report
- PMID: 39834667
- PMCID: PMC11744022
- DOI: 10.7759/cureus.77681
Successful Treatment of a Patient With Chronic Bronchiectasis Using an Induced Native Phage Cocktail: A Case Report
Abstract
Bronchiectasis is a well-recognized chronic respiratory disease characterized by a productive cough and multi-microbial activation syndrome (MMAS) of various respiratory infections due to what can be the permanent dilatation of the bronchi. Bronchiectasis represents an ongoing challenge to conventional antibiotic treatment as the damaged bronchial environment remains conducive to ongoing opportunistic infections and microbial mutations, leading to multi-drug resistance. Standard treatment guidelines are designed to promptly identify and address the primary infection. Despite the strong focus on identification of the primary infection in each new episode, by combining clinical history, and high-resolution computed tomography (HRCT), a high proportion of patients remain classified as "idiopathic". Important underlying infections, such as Aspergillus and other mold infections, Pseudomonas aeruginosa, Mycobacterium, Mycoplasma, and various viruses, are frequently not identified for prolonged periods of time, and selected broad-spectrum antibiotics are often ineffective. The introduction of Induced Native Phage Therapy in 2021 and Induced Native Phage cocktails in 2024 provides a new treatment alternative that induces naturally occurring phages to eliminate specifically targeted acute and chronic mixed infections even in cases of multi-drug resistant infections as seen in chronic bronchiectasis. This article will present the successful long-term results in a case study demonstrating the speed, gentleness, and effectiveness of induced native phage cocktails in a 45-year-old male with life-long asthma resulting in multi-microbial activation syndrome in severe non-cystic fibrosis bronchiectasis for the last 20 years.
Keywords: aspergillus; asthma; biofilm; bronchiectasis; endotoxin; induced native phage therapy; multi-microbial activation syndrome; mycobacterium; pseudomonas aeruginosa; staphylococcus.
Copyright © 2025, Jernigan et al.
Conflict of interest statement
Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Advarra issued approval Pro00064096. The single-site protocol titled, "The INPT/CMABM Registry: An Observational Study of the Dietary Supplement, Induced Native Phage Therapy, Combined with the Treatment Philosophies and Techniques of Chiropractic Medicine and American Biological/Bioregulatory Medicine (CMABM) has been approved to proceed. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: David A. Jernigan declare(s) employment from PhagenCorp. David A. Jernigan is the inventor of INPT (patent-pending), the owner of PhagenCorp, which produces the Inducen formulations, and the owner of the site for the IRB study, Biologix Center for Optimum Health, Franklin, Tennessee, U.S.A. Intellectual property info: Induced Native Phage Therapy (INPT) is presently patent-pending. Inducen formulations are copyright protected. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Similar articles
-
Induced Native Phage Cocktails for Multi-microbial Activation Syndrome in Treatment-Resistant Illnesses.Cureus. 2024 Oct 28;16(10):e72587. doi: 10.7759/cureus.72587. eCollection 2024 Oct. Cureus. 2024. PMID: 39474589 Free PMC article. Review.
-
Bronchiectasis: a case-based approach to investigation and management.Eur Respir Rev. 2018 Jul 11;27(149):180016. doi: 10.1183/16000617.0016-2018. Print 2018 Sep 30. Eur Respir Rev. 2018. PMID: 29997246 Free PMC article. Review.
-
Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review.Front Microbiol. 2018 May 4;9:775. doi: 10.3389/fmicb.2018.00775. eCollection 2018. Front Microbiol. 2018. PMID: 29780361 Free PMC article. Review.
-
The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):121-138. doi: 10.1089/jamp.2017.1415. Epub 2017 Oct 27. J Aerosol Med Pulm Drug Deliv. 2018. PMID: 29077527 Free PMC article. Review.
-
Temperate Bacteriophages from Chronic Pseudomonas aeruginosa Lung Infections Show Disease-Specific Changes in Host Range and Modulate Antimicrobial Susceptibility.mSystems. 2019 Jun 4;4(4):e00191-18. doi: 10.1128/mSystems.00191-18. mSystems. 2019. PMID: 31164451 Free PMC article.
Cited by
-
Carbapenem Resistance in Acinetobacter baumannii: Mechanisms, Therapeutics, and Innovations.Microorganisms. 2025 Jun 27;13(7):1501. doi: 10.3390/microorganisms13071501. Microorganisms. 2025. PMID: 40732008 Free PMC article. Review.
References
-
- An update on bronchiectasis. Moreschi MA, Fiel SB. https://journals.lww.com/co-pulmonarymedicine/abstract/1995/03000/an_upd.... Curr Opin Pulm Med. 1995;1:119–124. - PubMed
-
- Bird K, Memon J. StatPearls [Internet] Treasure Island: StatPearls Publishing; 2024. Bronchiectasis.
-
- Bacteriophages for bronchiectasis: treatment of the future? Dominic C, Pye HV, Mishra EK, Adriaenssens EM. Curr Opin Pulm Med. 2024;1:235–242. - PubMed
Publication types
LinkOut - more resources
Full Text Sources